A Phase 1 Study of REM-422 in People With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome


Full Title

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients with Relapsed/Refractory AML or Higher-Risk MDS


In this study, researchers want to find the best dose of REM-422 to treat leukemia or myelodysplastic syndrome (MDS). The people in this study have acute myeloid leukemia (AML) or higher-risk MDS that keeps growing even with treatment. Higher-risk means the disease has a high chance of coming back or not responding to therapy.

REM-422 reduces the amount of the MYB protein, which promotes cancer cell growth. REM-422 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have AML or higher-risk MDS that came back or keeps growing after treatment.
  • Have completed prior treatment at least 2 weeks before taking REM-422.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID